10x Genomics’ recurring consumables, spatial-biology leadership, and Atera rollout offer long-term upside, but near-term margin compression and a demanding valuation make execution the pivotal variable.
Overview
10x Genomics supplies integrated hardware, consumables, and software that let research and biopharma laboratories analyze biology at single-cell and spatial resolution. Chromium anchors single-cell genomics; Visium, Xenium, and newly launched Atera extend the company into spatial biology. Instruments establish an installed base that drives high-margin recurring assay kits, chips, beads, and reagents. Consumables generated **$134.3 million, or 89.1% of Q3 2026 revenue**, while Q3 total revenue was $150.7 million, up 1.1% year over year and above the $147.96 million consensus. Gross margin reached 75.0%, operating loss narrowed to $16.1 million, and net loss was $19.4 million. Management raised FY2026 revenue guidance to $625–$635 million, although normalized core growth is 4%–6% and Q4 gross margin is expected to fall to the low-to-mid-60% range as Atera shipments scale. The competitive position is supported by more than 10,000 publications, patents, and workflow switching costs. At $58.19, shares trade at 11.1x FY2026 guidance EV/sales, a premium that assumes durable consumable economics and spatial growth. The five-year probability-weighted target is $64.98; near-term catalysts are Atera placements, spatial pull-through, and manufacturing yield improvement.